Noriyuki Miyata Selected Research

Noriyuki Miyata Research Topics

Disease

5	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2006 - 04/2002
4	Hypertension (High Blood Pressure) 12/2023 - 08/2005
3	Fibrosis (Cirrhosis) 12/2023 - 06/2013
3	Proteinuria 12/2023 - 06/2013
3	Diabetic Nephropathies (Diabetic Nephropathy) 01/2021 - 06/2013
3	Brain Ischemia (Cerebral Ischemia) 03/2009 - 05/2006
3	Infarction (Infarctions) 03/2009 - 07/2005
3	Ischemic Stroke 12/2007 - 07/2005
3	Stroke (Strokes) 12/2007 - 07/2005
2	Kidney Diseases (Kidney Disease) 01/2021 - 08/2005
2	Hyperglycemia 07/2015 - 06/2013
2	Ureteral Obstruction 04/2008 - 12/2006
2	Reperfusion Injury 05/2006 - 08/2005
2	Intracranial Vasospasm 11/2005 - 07/2005
1	Hypertrophy 12/2023
1	Weight Gain 01/2023
1	Dysbiosis 01/2023
1	Arthritis (Polyarthritis) 01/2022
1	Rheumatoid Arthritis 01/2022
1	Body Weight (Weight, Body) 01/2022
1	Chronic Renal Insufficiency 01/2020
1	Anemia 01/2020
1	Weight Loss (Weight Reduction) 01/2019
1	Obesity 01/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 10/2013
1	Lymphoma (Lymphomas) 10/2013
1	Adrenal Insufficiency (Adrenal Gland Hypofunction) 10/2013
1	Combined Pituitary Hormone Deficiency 10/2013
1	Necrosis 06/2013
1	Type 2 Diabetes Mellitus (MODY) 04/2010
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2009
1	Hemorrhage 11/2005
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 08/2005
1	Pre-Eclampsia (Preeclampsia) 08/2005
1	Uremia 08/2005
1	Cerebral Hemorrhage 07/2005

Drug/Important Bio-Agent (IBA)

9	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 03/2009 - 04/2002
4	N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamideIBA 03/2009 - 07/2005
3	SaltsIBA 12/2023 - 07/2015
3	Sodium-Glucose Transporter 2 InhibitorsIBA 07/2015 - 04/2010
3	formamideIBA 03/2009 - 07/2005
2	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 07/2015 - 06/2013
2	Lisinopril (Prinivil)FDA LinkGeneric 07/2015 - 06/2013
2	Vasoconstrictor AgentsIBA 03/2009 - 02/2004
2	L-xylulose reductaseIBA 04/2008 - 12/2006
1	AlbuminsIBA 12/2023
1	Matrix Metalloproteinase InhibitorsIBA 12/2023
1	Matrix Metalloproteinases (MMPs)IBA 12/2023
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 12/2023
1	Adalimumab (Humira)FDA Link 01/2022
1	Tumor Necrosis Factor InhibitorsIBA 01/2022
1	Amino Acids FDA Link 01/2022
1	AntibodiesIBA 01/2022
1	thiamine triphosphorate (TTP)IBA 01/2022
1	Immunoglobulin G (IgG)IBA 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022
1	GTP-Binding Proteins (G-Protein)IBA 01/2021
1	Lysophosphatidic Acid ReceptorsIBA 01/2021
1	LipidsIBA 01/2021
1	lysophosphatidic acidIBA 01/2021
1	3- (4- (4- ((1- (2- chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acidIBA 01/2021
1	Erythropoietin FDA Link 01/2020
1	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 01/2020
1	Hemoglobins (Hemoglobin)IBA 01/2020
1	Prolyl-Hydroxylase InhibitorsIBA 01/2020
1	Sucrose (Saccharose)IBA 01/2019
1	LeptinIBA 01/2019
1	Streptozocin (Streptozotocin)FDA Link 07/2015
1	Methotrexate (Mexate)FDA LinkGeneric 10/2013
1	Sodium-Glucose Transport ProteinsIBA 06/2013
1	Insulin (Novolin)FDA Link 06/2013
1	Glucose (Dextrose)FDA LinkGeneric 04/2010
1	Sorbitol (Yal)FDA Link 04/2010
1	SodiumIBA 04/2010
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 03/2009
1	EicosanoidsIBA 03/2009
1	HET0016IBA 03/2009
1	20-hydroxyeicosa-6(Z),15(Z)-dienoic acidIBA 03/2009
1	Pyruvaldehyde (Methylglyoxal)IBA 04/2008
1	Glyoxal (Ethanedial)IBA 04/2008
1	3-deoxyglucosoneIBA 04/2008
1	Arachidonic Acid (Vitamin F)IBA 05/2006
1	triphenyltetrazoliumIBA 05/2006
1	Tissue Plasminogen Activator (Alteplase)FDA Link 05/2006

Therapy/Procedure

2	Therapeutics 10/2013 - 06/2013
1	Diet Therapy (Therapy, Diet) 01/2023
1	Drug Therapy (Chemotherapy) 10/2013
1	Hematopoietic Stem Cell Transplantation 10/2013